CoChat

Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril

Open access
Johnson, Eric S, Weinstein, Jessica R, Thorp, Micah L, Platt, Robert W, Petrik, Amanda F, Yang, Xiuhai, Anderson, Sharon, Smith, David H · 2010 · Pharmacoepidemiology and Drug Safety
Cited by 46

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose: Angiotensin‐converting enzyme (ACE) inhibitors are recommended for patients with chronic kidney disease (CKD) because they slow disease progression. But physicians' concerns about the risk of hyperkalemia (elevated serum potassium level), a potentially fatal adverse effect, may limit optimal management with ACE‐inhibitors. We synthesized known predictors of hyperkalemia into a prognostic risk score to predict the risk of hyperkalemia. Methods: We assembled a retrospective cohort of adult patients with possible CKD (at least one estimated glomerular filtration rate (eGFR) value less than 60 ml/min/1.73 m 2) who started an ACE‐inhibitor (i.e., incident users) between 1998 and 2006 at a health maintenance organization. We followed patients for hyperkalemia: (1) potassium value >5.5 mmol/L; or (2) diagnosis code for hyperkalemia. Cox regression synthesized a priori predictors recorded in the electronic medical record into a risk score. Results: We followed 5171 patients and 145 experienced hyperkalemia, a 90‐day risk of 2.8%. Predictors included: age, eGFR, diabetes, heart failure, potassium supplements, potassium‐sparing diuretics, and a high dose for the ACE‐inhibitor (lisinopril). The risk score separated high‐risk patients (top quintile, observed risk of 6.9%) from low‐risk patients (bottom quintile, observed risk of 0.7%). Predicted and observed risks agreed within 1% for each quintile. The risk increased gradually in relation to declining eGFR with no apparent threshold for contraindicating ACE‐inhibitors. Conclusions: The risk score separated high‐risk patients (who may need more intensive laboratory monitoring) from low‐risk patients. The risk score should be validated in other populations before it is ready for use in clinical practice. Copyright © 2010 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pds.1923

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 46

Metadata

Authors
Johnson, E. S., Weinstein, J. R., Thorp, M. L., Platt, R. W., Petrik, A. F., Yang, X., Anderson, S., & Smith, D. H.
Venue
Pharmacoepidemiology and Drug Safety
Publisher
Wiley
Published
2010-02-24
Volume
19
Issue
3
Pages
266-272
ISSN
  • 1053-8569 (ISSN-L)
  • 1099-1557
OpenAlex
W1988582819
Cited by
46
References
4
FWCI
2.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.